USA Financial Portformulas Corp acquired a new stake in Celgene Co. (NASDAQ:CELG) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 24,590 shares of the biopharmaceutical company’s stock, valued at approximately $3,586,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Capital Counsel LLC NY raised its position in shares of Celgene by 0.4% in the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC increased its position in Celgene by 0.6% during the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 11 shares in the last quarter. Flagship Harbor Advisors LLC increased its position in Celgene by 0.9% during the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after purchasing an additional 18 shares in the last quarter. Savant Capital LLC increased its position in Celgene by 0.9% during the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 20 shares in the last quarter. Finally, TCI Wealth Advisors Inc. increased its position in Celgene by 0.9% during the 2nd quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock worth $395,000 after purchasing an additional 26 shares in the last quarter. 79.74% of the stock is owned by institutional investors.
Shares of Celgene Co. (NASDAQ:CELG) opened at $104.58 on Friday. Celgene Co. has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The company has a market cap of $82,340.00, a PE ratio of 24.67, a PEG ratio of 0.68 and a beta of 1.77.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. Celgene had a net margin of 30.06% and a return on equity of 43.32%. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter last year, the company posted $1.58 earnings per share. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. sell-side analysts expect that Celgene Co. will post 6.68 EPS for the current year.
A number of equities analysts recently issued reports on CELG shares. BMO Capital Markets upped their price objective on shares of Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, November 17th. Oppenheimer reissued a “buy” rating and set a $170.00 target price on shares of Celgene in a report on Friday, October 20th. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 target price on the stock in a report on Monday, October 23rd. Cann reissued a “buy” rating on shares of Celgene in a report on Thursday, October 26th. Finally, Morgan Stanley raised shares of Celgene from an “underweight” rating to an “equal weight” rating in a research note on Friday, October 27th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have assigned a buy rating to the stock. Celgene has a consensus rating of “Buy” and an average price target of $131.18.
COPYRIGHT VIOLATION NOTICE: “24,590 Shares in Celgene Co. (CELG) Purchased by USA Financial Portformulas Corp” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/12/usa-financial-portformulas-corp-buys-new-stake-in-celgene-co-celg.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.